Bio-Path (NASDAQ:BPTH) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Saturday. The firm issued a sell rating on the stock.

Separately, Roth Mkm reissued a buy rating and issued a $20.00 price objective on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Trading Up 9.2 %

Shares of BPTH stock opened at $0.95 on Friday. Bio-Path has a twelve month low of $0.86 and a twelve month high of $21.60. The stock has a fifty day simple moving average of $1.30 and a two-hundred day simple moving average of $2.35.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the prior year, the firm earned ($10.60) EPS. Equities research analysts predict that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.